Prevalence and incidence of Entamoeba histolytica infection in South Africa and Egypt.
There are little data on the true prevalence and incidence of Entamoeba histolytica infection in Africa. This is due to the inability, historically, to differentiate Entamoeba histolytica from the more common, but non-pathogenic, Entamoeba dispar. In addition, newer studies have demonstrated that the previous gold standard, culture with zymodeme analysis, is insensitive in detecting the presence of infection, especially when compared to PCR. Recent published articles as well as data from the authors' previous work are reviewed and summarized to elucidate what is known about prevalence and incidence of Entamoeba histolytica in Africa. The majority of data on asymptomatic infection are published from South Africa, Egypt and Cote d'Ivoire. Egypt has high rates of asymptomatic infection detected in the stool (>21%), whereas South Africa and Cote d'Ivoire rates range between 0 and 2%. Seroprevalence estimates the rate of recent infection, because anti-amebic antibodies generally persist for <5 years. Seropositivity rates (IgG, IgA) range from approximately 10 to 20%, indicating recent infection in this proportion of the population. Entamoeba histolytica infects a significant proportion of many populations of Africa; however, little data are currently available to indicate true prevalence and incidence. Further studies are needed to determine the burden of infection and disease in Africa.
Stauffer
William
W
Department of Medicine, Division of Infectious Diseases & International Medicine, University of Minnesota, Minneapolis, Minnesota 55455, USA. stauf005@umn.edu
Abd-Alla
Mohamed
M
Ravdin
Jonathan I
JI
D000818:Animals; D004534:Egypt / Q000453:epidemiology; D004748:Entamoeba histolytica / Q000302:isolation & purification*; D004749:Entamoebiasis / Q000453:epidemiology* / Q000469:parasitology; D006801:Humans; D015994:Incidence; D015995:Prevalence; D013019:South Africa / Q000453:epidemiology